🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT03224312
Recruiting Observational

Chongqing Primary Aldosteronism Study

NCT03224312 · tracked via the Priya Life Science China tracker
Sponsor
Chongqing Medical University
Phase
Observational
Started
2016-10-01
Last updated
2023-09-06

Condition(s) studied

Primary Aldosteronism

Investigational drug(s) / intervention(s)

no intervention

no intervention: no intervention

Study summary

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. hypertensive patients who completed ARR screening and necessary further tests; 2. Voluntary to sign the informed consent. Exclusion Criteria: 1. patients with severe cardiac, hepatic or renal dysfunction; 2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Qifu Li Chongqing Chongqing Municipality Recruiting

More Chongqing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03224312 on ClinicalTrials.gov ↗ ← All trials in China